发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
Dying to survive: harnessing inflammatory cell death for better immunotherapy. 死中求生：利用炎性细胞死亡改善免疫疗法。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-21 DOI: 10.1016/j.trecan.2025.01.012
Long Cheng, Yibo Wang, Ying Zhang
{"title":"Dying to survive: harnessing inflammatory cell death for better immunotherapy.","authors":"Long Cheng, Yibo Wang, Ying Zhang","doi":"10.1016/j.trecan.2025.01.012","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.012","url":null,"abstract":"<p><p>Immunotherapy has transformed cancer treatment paradigms, but its effectiveness depends largely on the immunogenicity of the tumor. Unfortunately, the high resemblance of cancer to normal tissues makes most tumors immunologically 'cold', with a poor response to immunotherapy. Danger signals are critical for breaking immune tolerance and mobilizing robust, long-lasting antitumor immunity. Recent studies have identified inflammatory cell death modalities and their power in providing danger signals to trigger optimal tumor suppression. However, key mediators of inflammatory cell death are preferentially silenced during early tumor immunoediting. Strategies to rejuvenate inflammatory cell death hold great promise for broadening immunotherapy-responsive tumors. In this review, we examine how inflammatory cell death enhances tumor immunogenicity, how it is suppressed during immunoediting, and the potential of harnessing it for improved immunotherapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The enigma of maladaptation in gastric pathophysiology.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-20 DOI: 10.1016/j.trecan.2025.01.014
Gunter Maubach, Arun K Kanthasamy, Sandro Gogia, Michael Naumann
{"title":"The enigma of maladaptation in gastric pathophysiology.","authors":"Gunter Maubach, Arun K Kanthasamy, Sandro Gogia, Michael Naumann","doi":"10.1016/j.trecan.2025.01.014","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.014","url":null,"abstract":"<p><p>Despite a decline in global incidence, gastric cancer (GC) remains a major health concern. The development of GC is a sequential, multistage maladaptive process involving numerous different factors. Understanding the complexity of GC development is crucial for early detection, effective treatment, and, ultimately, prevention. In this respect, identifying the impact of risk factors contributing to the emergence or progression of GC, such as Helicobacter pylori infection, host and bacterial genetics, alcohol consumption, smoking, and preserved foods, will aid in combatting this disease. In this review, we focus on recent developments in understanding the role of the microbiome, dysfunctional molecular pathways, and immune evasion in gastric pathophysiology. We also highlight challenges and advances in treatment of GC.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-18 DOI: 10.1016/j.trecan.2025.02.002
Kostas A Papavassiliou, Nektarios Anagnostopoulos, Athanasios G Papavassiliou
{"title":"Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers.","authors":"Kostas A Papavassiliou, Nektarios Anagnostopoulos, Athanasios G Papavassiliou","doi":"10.1016/j.trecan.2025.02.002","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.02.002","url":null,"abstract":"<p><p>The molecular mechanisms of switch/sucrose nonfermentable (SWI/SNF)-related BAF chromatin remodeling complex subunit ATPase 2 (SMARCA2) degradation remain elusive. Recently, Kotagiri et al. revealed that SMARCA2 degradation induces enhancer reprogramming in SMARCA4-mutant lung cancer cells, rendering enhancers of key cell-cycle genes inaccessible and suppressing their expression. In addition, the authors identified that transcriptional enhanced associate domain (TEAD) inhibitors synergize with SMARCA2 degraders in inhibiting SMARCA4-mutant lung cancer growth.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143459697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Defining obesity in the context of cancer: thinking beyond body mass index.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-14 DOI: 10.1016/j.trecan.2025.01.009
Shuchi Gulati, William J Murphy
{"title":"Defining obesity in the context of cancer: thinking beyond body mass index.","authors":"Shuchi Gulati, William J Murphy","doi":"10.1016/j.trecan.2025.01.009","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.009","url":null,"abstract":"<p><p>Obesity is a condition of excess body fat. Although it has been identified as a risk factor for multiple cancers in part because of its 'metainflammatory' state, it has also been paradoxically associated with improved response to immune checkpoint inhibition. To study obesity, one must first understand how best to define it. In this opinion article, we briefly discuss factors that are impacting net effects of obesity and highlight complementary measures that should be considered beyond body mass index (BMI) when attempting to assess the potential effects of obesity in cancer.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-14 DOI: 10.1016/j.trecan.2025.01.011
Ludovic Gabellier, Enzo Bosetta, Maël Heiblig, Jean-Emmanuel Sarry
{"title":"Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations.","authors":"Ludovic Gabellier, Enzo Bosetta, Maël Heiblig, Jean-Emmanuel Sarry","doi":"10.1016/j.trecan.2025.01.011","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.011","url":null,"abstract":"<p><p>Pathogenic variants of isocitrate dehydrogenase 1 and 2 (IDH1/2) genes are present in approximately 20% of acute myeloid leukemia (AML) cases, resulting in the oncometabolite R-2-hydroxyglutarate (R-2-HG). The accumulation of R-2-HG in leukemic cells and in their niche induces epigenetic modifications, profound rewiring of the cellular metabolism, and microenvironmental remodeling. These changes promote cellular differentiation bias, enhancing the survival and proliferation of leukemic cells, and thus playing a pivotal role in leukemogenesis and resistance to standard AML therapy. This review focuses on the different perspectives offered by studying metabolism and resistance to standard treatments in AML with IDH1 or IDH2 pathogenic variants, for the development of new biomarkers and therapeutic solutions.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting PI3Kγ in cancer.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-12 DOI: 10.1016/j.trecan.2025.01.008
Giuliana P Mognol, Anghesom Ghebremedhin, Judith A Varner
{"title":"Targeting PI3Kγ in cancer.","authors":"Giuliana P Mognol, Anghesom Ghebremedhin, Judith A Varner","doi":"10.1016/j.trecan.2025.01.008","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.008","url":null,"abstract":"<p><p>The phosphoinositide 3-kinases (PI3Ks) have been the focus of a significant body of cancer research since their discovery nearly 40 years ago. These lipid kinases are now known to play central roles in cancer cell proliferation, survival, migration, metabolism, and immunity and serve as the target of numerous investigational and approved therapeutics. One of these kinases, the unique class IB PI3Kγ, which is highly expressed in myeloid lineage cells and myeloid leukemias, plays prominent roles in tumor immune suppression. Inhibition of this kinase has promoted improved antitumor immune responses in recent solid tumor preclinical studies and clinical trials. New studies also identify this kinase as a driver of acute myeloid leukemia self-renewal and as a new target for the treatment of aggressive leukemias.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy.
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-10 DOI: 10.1016/j.trecan.2025.01.007
Tatiana A Mishchenko, Oluwabukolami J Olajide, Ekaterina N Gorshkova, Maria V Vedunova, Dmitri V Krysko
{"title":"Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy.","authors":"Tatiana A Mishchenko, Oluwabukolami J Olajide, Ekaterina N Gorshkova, Maria V Vedunova, Dmitri V Krysko","doi":"10.1016/j.trecan.2025.01.007","DOIUrl":"https://doi.org/10.1016/j.trecan.2025.01.007","url":null,"abstract":"<p><p>Temozolomide (TMZ), the standard first-line chemotherapy for glioblastoma multiforme (GBM), has been a cornerstone of treatment despite its known limitations. We propose critically assessing TMZ's potential to induce multiple regulated cell death modalities and leveraging their immunogenic properties to develop novel strategies for overcoming the resistance of GBM and enhancing its therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":""},"PeriodicalIF":14.3,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation. 来自自噬-免疫检查点相互调节的癌症免疫治疗挑战。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2024-12-19 DOI: 10.1016/j.trecan.2024.11.001
Gang Zhang, Yinfeng Chen, Xing Huang, Tingbo Liang
{"title":"Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation.","authors":"Gang Zhang, Yinfeng Chen, Xing Huang, Tingbo Liang","doi":"10.1016/j.trecan.2024.11.001","DOIUrl":"10.1016/j.trecan.2024.11.001","url":null,"abstract":"<p><p>Multiple strategies have been clinically employed as combination partners to enhance the therapeutic efficacy of immune checkpoint inhibitors (ICIs). Although these combinations have demonstrated improved effectiveness in some instances, each presents its own limitations. Autophagy-targeting therapy offers several advantages when combined with ICIs, including enhanced tumor immunogenicity, reduced side effects, and broader applicability to diverse patient populations. However, emerging evidence reveals complex reciprocal regulation between autophagy and immune checkpoints which may complicate combination treatments targeting these two systems. This review focuses on the reciprocal interplay between autophagy and immune checkpoints, and provides valuable guidelines for the determination and adjustment of therapeutic regimens in the future.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"169-184"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142872923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Turning cold into hot: emerging strategies to fire up the tumor microenvironment. 化冷为热：激发肿瘤微环境的新策略。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2024-12-26 DOI: 10.1016/j.trecan.2024.11.011
Kaili Ma, Lin Wang, Wenhui Li, Tingting Tang, Bo Ma, Liyuan Zhang, Lianjun Zhang
{"title":"Turning cold into hot: emerging strategies to fire up the tumor microenvironment.","authors":"Kaili Ma, Lin Wang, Wenhui Li, Tingting Tang, Bo Ma, Liyuan Zhang, Lianjun Zhang","doi":"10.1016/j.trecan.2024.11.011","DOIUrl":"10.1016/j.trecan.2024.11.011","url":null,"abstract":"<p><p>The tumor microenvironment (TME) is a complex, highly structured, and dynamic ecosystem that plays a pivotal role in the progression of both primary and metastatic tumors. Precise assessment of the dynamic spatiotemporal features of the TME is crucial for understanding cancer evolution and designing effective therapeutic strategies. Cancer is increasingly recognized as a systemic disease, influenced not only by the TME, but also by a multitude of systemic factors, including whole-body metabolism, gut microbiome, endocrine signaling, and circadian rhythm. In this review, we summarize the intrinsic, extrinsic, and systemic factors contributing to the formation of 'cold' tumors within the framework of the cancer-immunity cycle. Correspondingly, we discuss potential strategies for converting 'cold' tumors into 'hot' ones to enhance therapeutic efficacy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"117-134"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142898416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional heterogeneity of fibroblasts in primary tumors and metastases. 原发性肿瘤和转移瘤中成纤维细胞的功能异质性。
IF 14.3 1区 医学
Trends in cancer Pub Date : 2025-02-01 Epub Date: 2024-12-13 DOI: 10.1016/j.trecan.2024.11.005
Priscilla S W Cheng, Marta Zaccaria, Giulia Biffi
{"title":"Functional heterogeneity of fibroblasts in primary tumors and metastases.","authors":"Priscilla S W Cheng, Marta Zaccaria, Giulia Biffi","doi":"10.1016/j.trecan.2024.11.005","DOIUrl":"10.1016/j.trecan.2024.11.005","url":null,"abstract":"<p><p>Cancer-associated fibroblasts (CAFs) are abundant components of the tumor microenvironment (TME) of most solid malignancies and have emerged as key regulators of cancer progression and therapy response. Although recent technological advances have uncovered substantial CAF molecular heterogeneity at the single-cell level, defining functional roles for most described CAF populations remains challenging. With the aim of bridging CAF molecular and functional heterogeneity, this review focuses on recently identified functional interactions of CAF subtypes with malignant cells, immune cells, and other stromal cells in primary tumors and metastases. Dissecting the heterogeneous functional crosstalk of specific CAF populations with other components is starting to uncover candidate combinatorial strategies for therapeutically targeting the TME and cancer progression.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"135-153"},"PeriodicalIF":14.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信